{"transactions":[{"id":734193,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-06-18T00:30:10.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":1980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."}],"balance_after":1980,"derivative":{"underlying":"Common Stock","underlying_shares":1980},"source":{"system":"sec-edgar","filing":"0001365617-26-000004","document":"form4-06172026_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000136561726000004/form4-06172026_080605.xml","form_type":"4"}},{"id":734192,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-18T00:30:10.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":3772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":3772,"derivative":{"exercise_price":101,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":3772},"source":{"system":"sec-edgar","filing":"0001365617-26-000004","document":"form4-06172026_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000136561726000004/form4-06172026_080605.xml","form_type":"4"}},{"id":744319,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T01:21:32.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":16667,"derivative":{"exercise_price":21.23,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001628280-26-042046","document":"wk-form4_1781054489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000162828026042046/wk-form4_1781054489.xml","form_type":"4"}},{"id":744318,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T01:21:32.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":5778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2025, maintained by the Company."}],"balance_after":32213,"source":{"system":"sec-edgar","filing":"0001628280-26-042046","document":"wk-form4_1781054489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000162828026042046/wk-form4_1781054489.xml","form_type":"4"}},{"id":748091,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-05T11:59:00.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":12500,"derivative":{"exercise_price":30.91,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-258435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526258435/ownership.xml","form_type":"4"}},{"id":930082,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-27T21:14:26.000Z","date":"2026-01-23","kind":"purchase","planned":false,"acquired":true,"shares":131425,"price":68.48,"value":8999984.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":459010,"source":{"system":"sec-edgar","filing":"0001365617-26-000002","document":"form4-01272026_090122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000136561726000002/form4-01272026_090122.xml","form_type":"4"}},{"id":930081,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-27T21:14:26.000Z","date":"2026-01-23","kind":"other","planned":false,"acquired":true,"shares":159277,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the \"Merger\"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the \"Merger\"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":327585,"source":{"system":"sec-edgar","filing":"0001365617-26-000002","document":"form4-01272026_090122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000136561726000002/form4-01272026_090122.xml","form_type":"4"}},{"id":1030612,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":5,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-30T20:59:56.000Z","date":"2025-09-26","kind":"purchase","planned":false,"acquired":true,"shares":666666,"price":18,"value":11999988.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5219440,"source":{"system":"sec-edgar","filing":"0001231919-25-000267","document":"form4-09302025_080948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000123191925000267/form4-09302025_080948.xml","form_type":"4"}},{"id":1037367,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T21:20:18.000Z","date":"2025-09-17","kind":"other","planned":false,"acquired":false,"shares":17199,"price":1.95,"value":33538.05,"ownership":{"direct":false,"nature":"By Patrick J. Heron"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit (\"RSU\") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001790879-25-000007","document":"form4-09172025_090911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000179087925000007/form4-09172025_090911.xml","form_type":"4"}},{"id":1037366,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T21:20:18.000Z","date":"2025-09-17","kind":"other","planned":false,"acquired":false,"shares":8535337,"price":1.95,"value":16643907.15,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation (\"Parent\") and XRA 4 Corp., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each share of the Issuer's Common Stock, par value $0.0001 per share (\"Shares\"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001790879-25-000007","document":"form4-09172025_090911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000179087925000007/form4-09172025_090911.xml","form_type":"4"}},{"id":1101574,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:07:01.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":17199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date."}],"balance_after":17199,"source":{"system":"sec-edgar","filing":"0000950170-25-090020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000095017025090020/ownership.xml","form_type":"4"}},{"id":1107623,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T21:45:01.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":2646,"price":13.0803,"value":34610.4738,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.945 to $13.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":27448,"source":{"system":"sec-edgar","filing":"0001415889-25-017576","document":"form4-06172025_090658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925017576/form4-06172025_090658.xml","form_type":"4"}},{"id":1109513,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T00:17:48.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":20568,"derivative":{"exercise_price":13.5,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20568},"source":{"system":"sec-edgar","filing":"0002065881-25-000027","document":"wk-form4_1750119461.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000206588125000027/wk-form4_1750119461.xml","form_type":"4"}},{"id":1109512,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:17:48.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":7609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.  Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 23, 2024, maintained by the Company."}],"balance_after":26435,"source":{"system":"sec-edgar","filing":"0002065881-25-000027","document":"wk-form4_1750119461.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000206588125000027/wk-form4_1750119461.xml","form_type":"4"}},{"id":1119297,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T12:44:37.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":378,"price":13.4108,"value":5069.2824,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.21 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":24802,"source":{"system":"sec-edgar","filing":"0001415889-25-015883","document":"form4-06062025_120633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925015883/form4-06062025_120633.xml","form_type":"4"}},{"id":1119296,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T12:44:37.000Z","date":"2025-06-04","kind":"purchase","planned":false,"acquired":true,"shares":1890,"price":13.3214,"value":25177.446,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.26 to $13.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":24424,"source":{"system":"sec-edgar","filing":"0001415889-25-015883","document":"form4-06062025_120633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925015883/form4-06062025_120633.xml","form_type":"4"}},{"id":1119778,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-06T12:02:29.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":16000,"derivative":{"exercise_price":11.86,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-082699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025082699/ownership.xml","form_type":"4"}},{"id":1127757,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2025-06-02T23:39:26.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":3977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."}],"balance_after":3977,"derivative":{"underlying":"Common Stock","underlying_shares":3977},"source":{"system":"sec-edgar","filing":"0001415889-25-015305","document":"form4-06022025_110622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015305/form4-06022025_110622.xml","form_type":"4"}},{"id":1127756,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T23:39:26.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":6268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting."}],"balance_after":6268,"derivative":{"exercise_price":44,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":6268},"source":{"system":"sec-edgar","filing":"0001415889-25-015305","document":"form4-06022025_110622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015305/form4-06022025_110622.xml","form_type":"4"}},{"id":1127755,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-02T23:39:26.000Z","date":"2025-05-29","kind":"exercise","planned":false,"acquired":false,"shares":5703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5703},"source":{"system":"sec-edgar","filing":"0001415889-25-015305","document":"form4-06022025_110622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015305/form4-06022025_110622.xml","form_type":"4"}},{"id":1127754,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:39:26.000Z","date":"2025-05-29","kind":"exercise","planned":false,"acquired":true,"shares":5703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer)."}],"balance_after":5703,"source":{"system":"sec-edgar","filing":"0001415889-25-015305","document":"form4-06022025_110622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015305/form4-06022025_110622.xml","form_type":"4"}},{"id":1134884,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:04:50.000Z","date":"2025-05-22","kind":"purchase","planned":false,"acquired":true,"shares":2520,"price":13.65,"value":34398.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":22534,"source":{"system":"sec-edgar","filing":"0001415889-25-014415","document":"form4-05232025_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925014415/form4-05232025_080546.xml","form_type":"4"}},{"id":1134883,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:04:50.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":2520,"price":13.66,"value":34423.2,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":20014,"source":{"system":"sec-edgar","filing":"0001415889-25-014415","document":"form4-05232025_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925014415/form4-05232025_080546.xml","form_type":"4"}},{"id":1142126,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T20:14:58.000Z","date":"2025-05-15","kind":"purchase","planned":false,"acquired":true,"shares":2520,"price":13.6178,"value":34316.856,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.49 to $13.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":17494,"source":{"system":"sec-edgar","filing":"0001415889-25-013620","document":"form4-05192025_080553.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925013620/form4-05192025_080553.xml","form_type":"4"}},{"id":1147081,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:18:54.000Z","date":"2025-05-14","kind":"purchase","planned":false,"acquired":true,"shares":6300,"price":13.7605,"value":86691.15,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.5643 to $13.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":14974,"source":{"system":"sec-edgar","filing":"0001415889-25-013137","document":"form4-05152025_080550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925013137/form4-05152025_080550.xml","form_type":"4"}},{"id":1147080,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:18:54.000Z","date":"2025-05-13","kind":"purchase","planned":false,"acquired":true,"shares":2374,"price":13.7577,"value":32660.7798,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.70 to $13.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":8674,"source":{"system":"sec-edgar","filing":"0001415889-25-013137","document":"form4-05152025_080550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925013137/form4-05152025_080550.xml","form_type":"4"}},{"id":1150531,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-13T20:11:38.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":6300,"price":13.6018,"value":85691.34,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.1504 to $13.9266, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":6300,"source":{"system":"sec-edgar","filing":"0001415889-25-012768","document":"form4-05132025_080532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588925012768/form4-05132025_080532.xml","form_type":"4"}},{"id":1163275,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-04-30T11:00:05.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates."}],"balance_after":22500,"derivative":{"exercise_price":13.75,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-060553","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000095017025060553/ownership.xml","form_type":"4"}},{"id":1200015,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:04:31.000Z","date":"2025-03-17","kind":"purchase","planned":false,"acquired":true,"shares":21,"price":43.9338,"value":922.6098,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.925 to $43.945, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":168672,"source":{"system":"sec-edgar","filing":"0001415889-25-008439","document":"form4-03182025_090327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925008439/form4-03182025_090327.xml","form_type":"4"}},{"id":1200014,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:04:31.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":528,"price":44.1125,"value":23291.4,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $44.00 to $44.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":168651,"source":{"system":"sec-edgar","filing":"0001415889-25-008439","document":"form4-03182025_090327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925008439/form4-03182025_090327.xml","form_type":"4"}},{"id":1209818,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T20:51:20.000Z","date":"2025-03-11","kind":"purchase","planned":false,"acquired":true,"shares":963,"price":43.7748,"value":42155.1324,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.405 to $44, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":168123,"source":{"system":"sec-edgar","filing":"0001415889-25-007828","document":"form4-03122025_080317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007828/form4-03122025_080317.xml","form_type":"4"}},{"id":1209817,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T20:51:20.000Z","date":"2025-03-10","kind":"purchase","planned":false,"acquired":true,"shares":577,"price":43.368,"value":25023.336,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.20 to $43.50, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":167160,"source":{"system":"sec-edgar","filing":"0001415889-25-007828","document":"form4-03122025_080317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007828/form4-03122025_080317.xml","form_type":"4"}},{"id":1209816,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T20:51:20.000Z","date":"2025-03-10","kind":"purchase","planned":false,"acquired":true,"shares":758,"price":42.6642,"value":32339.4636,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":166583,"source":{"system":"sec-edgar","filing":"0001415889-25-007828","document":"form4-03122025_080317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007828/form4-03122025_080317.xml","form_type":"4"}},{"id":1215124,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-10T21:12:58.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":580,"price":43.2145,"value":25064.41,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.79 to $43.42, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":165825,"source":{"system":"sec-edgar","filing":"0001415889-25-007540","document":"form4-03102025_090354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007540/form4-03102025_090354.xml","form_type":"4"}},{"id":1215123,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-10T21:12:58.000Z","date":"2025-03-06","kind":"purchase","planned":false,"acquired":true,"shares":1335,"price":43.8928,"value":58596.888,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $44.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":165245,"source":{"system":"sec-edgar","filing":"0001415889-25-007540","document":"form4-03102025_090354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007540/form4-03102025_090354.xml","form_type":"4"}},{"id":1219654,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-06T22:30:45.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":267,"price":44.545,"value":11893.515,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":163910,"source":{"system":"sec-edgar","filing":"0001415889-25-007260","document":"form4-03062025_100339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007260/form4-03062025_100339.xml","form_type":"4"}},{"id":1219653,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-06T22:30:45.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":56,"price":45.9597,"value":2573.7432,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $45.935 to $45.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":163643,"source":{"system":"sec-edgar","filing":"0001415889-25-007260","document":"form4-03062025_100339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007260/form4-03062025_100339.xml","form_type":"4"}},{"id":1219652,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-06T22:30:45.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":1279,"price":45.5486,"value":58256.6594,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $44.935 to $45.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":163587,"source":{"system":"sec-edgar","filing":"0001415889-25-007260","document":"form4-03062025_100339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925007260/form4-03062025_100339.xml","form_type":"4"}},{"id":1401657,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:39:00.000Z","date":"2024-09-18","kind":"purchase","planned":false,"acquired":true,"shares":115,"price":37.4,"value":4301.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":162308,"source":{"system":"sec-edgar","filing":"0001415889-24-023777","document":"form4-09202024_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924023777/form4-09202024_080957.xml","form_type":"4"}},{"id":1405180,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:09:12.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":28297265,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2353769},"source":{"system":"sec-edgar","filing":"0000950170-24-107530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107530/ownership.xml","form_type":"4"}},{"id":1405179,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:09:12.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":18922852,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1574005},"source":{"system":"sec-edgar","filing":"0000950170-24-107530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107530/ownership.xml","form_type":"4"}},{"id":1405178,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:09:12.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4552774,"source":{"system":"sec-edgar","filing":"0000950170-24-107530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107530/ownership.xml","form_type":"4"}},{"id":1405177,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:09:12.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":3927774,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3927774,"source":{"system":"sec-edgar","filing":"0000950170-24-107530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107530/ownership.xml","form_type":"4"}},{"id":1407717,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:04:18.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":15963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":15963,"derivative":{"exercise_price":16,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":15963},"source":{"system":"sec-edgar","filing":"0000950170-24-106439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024106439/ownership.xml","form_type":"4"}},{"id":1410856,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:04:14.000Z","date":"2024-09-06","kind":"purchase","planned":false,"acquired":true,"shares":230,"price":41.5783,"value":9563.009,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.50 to $41.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":162193,"source":{"system":"sec-edgar","filing":"0001415889-24-023154","document":"form4-09102024_090910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924023154/form4-09102024_090910.xml","form_type":"4"}},{"id":1474803,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T20:52:14.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":27052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service."}],"balance_after":27052,"derivative":{"exercise_price":8.63,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":27052},"source":{"system":"sec-edgar","filing":"0001787306-24-000104","document":"wk-form4_1718743928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000178730624000104/wk-form4_1718743928.xml","form_type":"4"}},{"id":1474802,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-18T20:52:14.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":10139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders.  The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.  The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":18826,"source":{"system":"sec-edgar","filing":"0001787306-24-000104","document":"wk-form4_1718743928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000178730624000104/wk-form4_1718743928.xml","form_type":"4"}},{"id":1486946,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-07T22:22:06.000Z","date":"2024-06-05","kind":"grant","planned":true,"acquired":true,"shares":5703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."}],"balance_after":5703,"derivative":{"underlying":"Common Stock","underlying_shares":5703},"source":{"system":"sec-edgar","filing":"0001415889-24-016066","document":"form4-06072024_100603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924016066/form4-06072024_100603.xml","form_type":"4"}},{"id":1486945,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T22:22:06.000Z","date":"2024-06-05","kind":"grant","planned":true,"acquired":true,"shares":8779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting."}],"balance_after":8779,"derivative":{"exercise_price":26.3,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":8779},"source":{"system":"sec-edgar","filing":"0001415889-24-016066","document":"form4-06072024_100603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924016066/form4-06072024_100603.xml","form_type":"4"}},{"id":1545339,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:22:13.000Z","date":"2024-04-04","kind":"purchase","planned":false,"acquired":true,"shares":8850,"price":14.5,"value":128325.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences X, L.P.  FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8544187,"source":{"system":"sec-edgar","filing":"0001415889-24-010490","document":"form4-04082024_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588924010490/form4-04082024_080405.xml","form_type":"4"}},{"id":1590989,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-06T21:28:21.000Z","date":"2024-03-04","kind":"purchase","planned":false,"acquired":true,"shares":21052,"price":9.5,"value":199994.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences VIII, L.P.  FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.  The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":8785284,"source":{"system":"sec-edgar","filing":"0001415889-24-007040","document":"form4-03062024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000141588924007040/form4-03062024_090313.xml","form_type":"4"}},{"id":1742372,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T21:35:02.000Z","date":"2023-11-09","kind":"purchase","planned":false,"acquired":true,"shares":2910,"price":28.3,"value":82353.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":161963,"source":{"system":"sec-edgar","filing":"0001209191-23-055180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123055180/doc4.xml","form_type":"4"}},{"id":1754655,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T20:09:29.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":80000,"price":2.5,"value":200000.0,"ownership":{"direct":true},"balance_after":8764232,"source":{"system":"sec-edgar","filing":"0001209191-23-053662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123053662/doc4.xml","form_type":"4"}},{"id":1780178,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T20:56:57.000Z","date":"2023-09-13","kind":"purchase","planned":false,"acquired":true,"shares":2625,"price":31.019,"value":81424.875,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.9633 to $31.0499, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":159053,"source":{"system":"sec-edgar","filing":"0001209191-23-049614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123049614/doc4.xml","form_type":"4"}},{"id":1782134,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:39:13.000Z","date":"2023-09-12","kind":"purchase","planned":false,"acquired":true,"shares":3750,"price":30.6037,"value":114763.875,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.2781 to $30.7970, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":156428,"source":{"system":"sec-edgar","filing":"0001209191-23-049292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123049292/doc4.xml","form_type":"4"}},{"id":1782133,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:39:13.000Z","date":"2023-09-11","kind":"purchase","planned":false,"acquired":true,"shares":4687,"price":30.3024,"value":142027.3488,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.0968 to $30.4835, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":152678,"source":{"system":"sec-edgar","filing":"0001209191-23-049292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123049292/doc4.xml","form_type":"4"}},{"id":1789327,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-05T16:51:37.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":147991,"price":26.25,"value":3884763.75,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":147991,"source":{"system":"sec-edgar","filing":"0001209191-23-048086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123048086/doc4.xml","form_type":"4"}},{"id":1855968,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T21:38:31.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":28.97,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037123/doc4.xml","form_type":"4"}},{"id":1860181,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2023-06-09T22:33:51.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates."}],"balance_after":22500,"derivative":{"exercise_price":17.94,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-23-015277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000089924323015277/doc4.xml","form_type":"4"}},{"id":1869207,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T23:16:34.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023."}],"balance_after":12220,"derivative":{"exercise_price":7.51,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12220},"source":{"system":"sec-edgar","filing":"0001787306-23-000062","document":"wk-form4_1685747781.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000178730623000062/wk-form4_1685747781.xml","form_type":"4"}},{"id":1869206,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T23:16:34.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":8687,"source":{"system":"sec-edgar","filing":"0001787306-23-000062","document":"wk-form4_1685747781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000178730623000062/wk-form4_1685747781.xml","form_type":"4"}},{"id":2175933,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-08-23T20:35:20.000Z","date":"2022-08-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":12.38,"expiration_date":"2032-08-18","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-029526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000089924322029526/doc4.xml","form_type":"4"}},{"id":2190582,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T20:34:26.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":250000,"price":20,"value":5000000.0,"ownership":{"direct":true},"balance_after":8684232,"source":{"system":"sec-edgar","filing":"0001209191-22-045014","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122045014/doc4.xml","form_type":"4"}},{"id":2242490,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T21:57:07.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":23.51,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-034630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919122034630/doc4.xml","form_type":"4"}},{"id":2243952,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:53:24.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022."}],"balance_after":11796,"derivative":{"exercise_price":20.29,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":11796},"source":{"system":"sec-edgar","filing":"0001567619-22-012314","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761922012314/doc1.xml","form_type":"4"}},{"id":2243951,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-03T20:53:24.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":4312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,312 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":4312,"source":{"system":"sec-edgar","filing":"0001567619-22-012314","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761922012314/doc1.xml","form_type":"4"}},{"id":2283867,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Notes","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":37212795.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":2736234},"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2283866,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"purchase","acquired":true,"shares":1764706,"price":17,"value":30000002.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8535337,"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2283865,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":2736234,"price":13.6,"value":37212782.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":6770631,"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2394081,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":5,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T22:00:58.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":112665,"price":7.1006,"value":799989.099,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1484115,"source":{"system":"sec-edgar","filing":"0001209191-22-009821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122009821/doc4.xml","form_type":"4"}},{"id":2562906,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1200000,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2562905,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"disposition_to_issuer","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Life Sciences VIII, L.P. entered into an Exchange Agreement with the Issuer pursuant to which, Frazier Life Sciences VIII, L.P. exchanged, on a 1:1 basis, 1,200,000 shares of the Issuer's Common Stock for a prefunded warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of  $0.001 per share (the \"Pre-Funded Warrant\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1371450,"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2629058,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":225850,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":225850},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629057,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":740673,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":740673},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629056,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A  Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":1199890,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1199890},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629055,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":64360,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":64360},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629054,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":211069,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":211069},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629053,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A  Preferred Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":false,"shares":341932,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":341932},"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629052,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":225850,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2312331,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629051,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":740673,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2086481,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629050,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":1199890,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1345808,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629049,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":64360,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":658943,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629048,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":211069,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":594583,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629047,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"exercise","acquired":true,"shares":341932,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":383514,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629046,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"purchase","acquired":true,"shares":145918,"price":16,"value":2334688.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Frazier Healthcare VII, L.P. (\"FH VII\"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":145918,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2629045,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":137190,"kind":"organization","name":"FHM VII, L.L.C.","position":2,"cik":"0001654631","reported_name":"FHM VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137191,"kind":"organization","name":"FHM VII, L.P.","position":3,"cik":"0001654632","reported_name":"FHM VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137192,"kind":"organization","name":"Frazier Healthcare VII, L.P.","position":4,"cik":"0001553071","reported_name":"Frazier Healthcare VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137193,"kind":"organization","name":"Frazier Healthcare VII-A, L.P.","position":5,"cik":"0001575192","reported_name":"Frazier Healthcare VII-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:54:29.000Z","date":"2021-07-20","kind":"purchase","acquired":true,"shares":41582,"price":16,"value":665312.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Frazier Healthcare VII-A, L.P. (\"FH VIIA\"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":41582,"source":{"system":"sec-edgar","filing":"0001567619-21-013730","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013730/doc1.xml","form_type":"4"}},{"id":2630085,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T20:10:23.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from July 15, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":23809,"derivative":{"exercise_price":16,"expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":23809},"source":{"system":"sec-edgar","filing":"0001567619-21-013640","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921013640/doc1.xml","form_type":"4"}},{"id":2671492,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T20:35:14.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":13391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":13391,"derivative":{"exercise_price":27.77,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":13391},"source":{"system":"sec-edgar","filing":"0001567619-21-012025","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365617/000156761921012025/doc1.xml","form_type":"4"}},{"id":2677907,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-08T20:51:31.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":16.88,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919121038951/doc4.xml","form_type":"4"}},{"id":2683269,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-03T22:51:16.000Z","date":"2021-06-02","kind":"grant","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":15000,"derivative":{"exercise_price":21.49,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-037903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919121037903/doc4.xml","form_type":"4"}},{"id":2715984,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata in-kind stock distribution by FHM Life Sciences VIII, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715983,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":true,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects shares of Common Stock received from FLS VIII in the in-kind stock distribution described herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":96574,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715982,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":2108558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata in-kind stock distribution by Frazier Life Sciences VIII, L.P. (\"FLS VIII\") to its limited partners and general partner for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents shares held of record by FLS VIII. The general partner of FLS VIII is FHM Life Sciences VIII, L.P., and the general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. James Topper and Patrick Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FLS VIII. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8434232,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2948245,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":333333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of the Issuer. By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each such person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Life Sciences X, L.P. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":333333,"derivative":{"exercise_price":11.5,"underlying":"Class A Ordinary Shares","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948244,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":167000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the \"Board\") of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each of such entity or person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":167000,"derivative":{"exercise_price":11.5,"underlying":"Class A Ordinary Shares","underlying_shares":167000},"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948243,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":1000000,"price":10,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of the Issuer. By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each such person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Life Sciences X, L.P. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948242,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":501000,"price":10,"value":5010000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the \"Board\") of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each of such entity or person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":501000,"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":3003145,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214281},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003144,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1390376,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1390376},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003143,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1917157,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}}],"next_cursor":"2020-10-21T00:01:18.000000Z,3003143"}